These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22894962)

  • 1. Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer.
    Sasada T; Noguchi M; Yamada A; Itoh K
    Hum Vaccin Immunother; 2012 Sep; 8(9):1309-13. PubMed ID: 22894962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized peptide vaccine for treatment of advanced cancer.
    Sasada T; Yamada A; Noguchi M; Itoh K
    Curr Med Chem; 2014; 21(21):2332-45. PubMed ID: 24524766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Peptide vaccination for castration-resistant prostate cancer].
    Koga N; Noguchi M
    Nihon Rinsho; 2014 Dec; 72(12):2147-51. PubMed ID: 25518349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
    Noguchi M; Sasada T; Itoh K
    Cancer Immunol Immunother; 2013 May; 62(5):919-29. PubMed ID: 23197273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospect and progress of personalized peptide vaccinations for advanced cancers.
    Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
    Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
    Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Personalized peptide vaccination].
    Itoh K; Takahashi R; Yoshitomi M; Terasaki M; Noguchi M
    Nihon Rinsho; 2012 Dec; 70(12):2118-23. PubMed ID: 23259383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of immunotherapy for the treatment of biliary tract cancer.
    Takahashi R; Yoshitomi M; Yutani S; Shirahama T; Noguchi M; Yamada A; Itoh K; Sasada T
    Hum Vaccin Immunother; 2013 May; 9(5):1069-72. PubMed ID: 23376808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
    Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
    Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
    Suekane S; Yutani S; Yamada A; Sasada T; Matsueda S; Takamori S; Toh U; Kawano K; Yoshiyama K; Sakamoto S; Sugawara S; Komatsu N; Yamada T; Naito M; Terasaki M; Mine T; Itoh K; Shichijo S; Noguchi M
    Int J Oncol; 2020 Jun; 56(6):1479-1489. PubMed ID: 32236612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
    Noguchi M; Koga N; Moriya F; Suekane S; Yutani S; Yamada A; Shichijo S; Kakuma T; Itoh K
    Cancer Sci; 2018 Sep; 109(9):2660-2669. PubMed ID: 29938870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
    Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
    Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.
    Shirahama T; Muroya D; Matsueda S; Yamada A; Shichijo S; Naito M; Yamashita T; Sakamoto S; Okuda K; Itoh K; Sasada T; Yutani S
    Cancer Sci; 2017 May; 108(5):838-845. PubMed ID: 28188670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.
    Sakamoto S; Yamada T; Terazaki Y; Yoshiyama K; Sugawara S; Takamori S; Matsueda S; Shichijo S; Yamada A; Noguchi M; Itoh K; Hattori N; Kohno N; Sasada T
    Clin Lung Cancer; 2017 Nov; 18(6):e385-e394. PubMed ID: 28416261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
    Noguchi M; Fujimoto K; Arai G; Uemura H; Hashine K; Matsumoto H; Fukasawa S; Kohjimoto Y; Nakatsu H; Takenaka A; Fujisawa M; Uemura H; Naito S; Egawa S; Fujimoto H; Hinotsu S; Itoh K
    Oncol Rep; 2021 Jan; 45(1):159-168. PubMed ID: 33200227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
    Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
    J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized peptide vaccines and their relation to other therapies in urological cancer.
    Kimura T; Egawa S; Uemura H
    Nat Rev Urol; 2017 Aug; 14(8):501-510. PubMed ID: 28561807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer.
    Uchino Y; Muroya D; Yoshitomi M; Shichijo S; Yamada A; Sasada T; Yamada T; Okuda K; Itoh K; Yutani S
    Mol Clin Oncol; 2021 Feb; 14(2):39. PubMed ID: 33437477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Personalized peptide vaccine for cancer treatment; now and its future].
    Waki K; Yamada A
    Nihon Rinsho; 2017 Feb; 75(2):251-256. PubMed ID: 30562860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
    Yamada T; Terazaki Y; Sakamoto S; Yoshiyama K; Matsueda S; Komatsu N; Waki K; Yamada A; Kawahara A; Kage M; Sugawara S; Yamashita Y; Sasada T; Takamori S; Itoh K
    Int J Oncol; 2015 Jan; 46(1):55-62. PubMed ID: 25310280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.